Cerapedics, Inc. appears in FDA device records as the applicant for a single premarket approval, P240001, covering the PearlMatrix™ P-15 Peptide Enhanced Bone Graft, also listed as PearlMatrix™ Bone Graft. The supplied filing snapshot links two PMA records to this applicant, both under product code NOX, device class 3, with the Orthopedic advisory committee recorded. One is the original approval and the other a later manufacturing-process supplement. The company's documented identity for industry readers rests on that device family and its stated composition rather than on any verified corporate parent, brand owner or commercial footprint. [1][2][3]

The approved device and its stated composition

The instructions for use describe PearlMatrix P-15 Peptide Enhanced Bone Graft as a composite of synthetic P-15 peptide bound to calcium phosphate particles within a collagen matrix carrier. The calcium phosphate component is termed anorganic bone mineral and described as porous, irregularly shaped particles spanning 106–1000 microns, with an average size of 481 microns. The IFU identifies P-15 peptide as the active agent. The SSED lists the generic name as peptide enhanced bone graft substitute and names PearlMatrix P-15 Peptide Enhanced Bone Graft, also called PearlMatrix Bone Graft. [6][7][8][3]

The FDA record lists the generic name as filler, bone void, synthetic peptide, with device name filler, bone void, synthetic peptide, under product code NOX and device class 3. The SSED records that breakthrough device status was granted on April 14, 2021, and that no panel recommendation date is listed. [1][2][3]

Original approval and its recorded scope

PMA P240001 received an approval decision dated June 18, 2025, according to the FDA record; the SSED states the date of FDA notice of approval as June 18, 2025, and that the applicant's manufacturing facilities were inspected and found in compliance with the device Quality System regulation. The approval order is referenced for post-approval requirements and restrictions, and directions for use point to device labeling. [2][3]

The approved indication recorded in the FDA entry covers intervertebral body fusion of the spine in skeletally mature patients, for use with a PEEK TLIF fusion device and supplemental internal spinal fixation systems cleared by the FDA for use in the lumbosacral spine, in patients with at least six months of non-operative treatment, at one level in the lumbar spine (L2-S1) for degenerative disc disease with up to Grade I spondylolisthesis. [2]

The 2026 manufacturing supplement

Supplement P240001/S003 was received on August 24, 2026, and decided on September 16, 2026, with decision code OK30 under supplement type 30-Day Notice. The supplement reason is recorded as a process change affecting manufacturer, sterilizer, packager or supplier. The applicant's own statement describes changes to P-15 manufacturing occurring at Bachem Americas due to equipment technological advancements and to improve process efficiency, along with a series of minor or administrative specification changes. [1]

The FDA database entry for P240001 carries a note that the device has supplements and that the device description, function or indication may have changed, directing readers to the supplements for current information and identifying the displayed labeling as the version at the time of approval. [4]

How to read the supplied filing snapshot

The supplied collection contains two linked PMA records, with decision counts of one OK30 and one APPR; the smaller record sample of two entries shows the same one-and-one split. These figures describe the supplied filings as of the snapshot date and are not measures of total company sales, total portfolio or safety performance. No recall records appear in the supplied sample. [1][2]

The instructions for use documents carry document numbers 40002-14-0, 40002-14-1 and 40002-14-2 and identify Cerapedics Inc. at 11025 Dover Street, Suite 1600, Westminster, CO 80021 USA as the entity for which the device is manufactured. That filing address is not treated here as a verified headquarters, and no parent, brand owner, customer or commercial availability is established by the public documents. [6][7][8]